Compare RAPT & ZEPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAPT | ZEPP |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Manufacturing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.4M | 406.0M |
| IPO Year | 2019 | N/A |
| Metric | RAPT | ZEPP |
|---|---|---|
| Price | $35.10 | $27.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 433.7K | 173.7K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $233,274,000.00 |
| Revenue This Year | N/A | $887.39 |
| Revenue Next Year | N/A | $26.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.64 |
| 52 Week Low | $5.67 | $2.13 |
| 52 Week High | $42.39 | $61.85 |
| Indicator | RAPT | ZEPP |
|---|---|---|
| Relative Strength Index (RSI) | 56.26 | 46.53 |
| Support Level | $34.38 | $27.24 |
| Resistance Level | $36.92 | $30.39 |
| Average True Range (ATR) | 2.56 | 2.07 |
| MACD | -0.11 | 0.39 |
| Stochastic Oscillator | 50.37 | 49.41 |
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.